# US 2026/0306514 A1 · Oral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306514 A1
- Document ID: US20260306514A1
- Status: Published application
- Kind: A1
- Application number: 19/125,889
- Filed: 2023-11-02
- Published: 2026-10-08
- Earliest claimed: 2022-11-02
- Assignees: Cadrenal Therapeutics, Inc.
- Applicants: Cadrenal Therapeutics, Inc.
- Inventors: David Maloney; Henry Flanner; Matthew Boxer
- Web page: https://patentgrep.com/patent/US20260306514A1

## CPC

- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/63: Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are pharmaceutical formulations comprising 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitors with improved solubility for oral administration. Also provides are pharmaceutical formulations comprising selective 12-LOX inhibitors with high drug loading of 30% or more amorphously dispersed in selected from vinylpyrollidone-vinyl acetate copolymers (Kollidon VA64), amino methacrylate copolymer (Eudragit EPO), Hydroxypropylmethylcellulose E3 (HPMC E3), or a combination thereof and make up 40 to 80% of the total solid content of the formulation. The formulation alternatively contains additives such as surfactants (sodium lauryl sulfate), crystal inhibitors, or pH modifiers up to 20% of the total solid content of the formulation.

## Claims

### Claim 1

A pharmaceutical formulation comprising:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

### Claim 2

A pharmaceutical formulation comprising:
or a pharmaceutically acceptable salt thereof, or diastereomers thereof; and a pharmaceutically acceptable carrier.

### Claim 3

A pharmaceutical formulation comprising:
or a pharmaceutically acceptable salt thereof, or diastereomers thereof; and a pharmaceutically acceptable carrier.

### Claim 4

A pharmaceutical formulation comprising a compound of Formula (I):
wherein
R1 is methoxy;
R2 is H; and
R3 is selected from the group consisting of 2-benzothiazole, 4-methyl-2-benzothiazole, 6-fluoro-2-benzothiazole, 6-methoxy-2-benzothiazole, 2-benzoxazole, 2-benzimidazole, 2-thiophene, 4-methyl-2-thiazole, 5-methyl-2-thiazole, 4,5-methyl-2-thiazole, 4-phenyl-2-thiazole, 3-quinoline, 8-isoquinoline, phenyl, 1,4-biphenyl, 1-naphthalene, 2-naphthalene, 3-piperazine-phenyl, 4-piperidine-phenyl, 3-piperidine-phenyl, 2-pyridine, 3-pyridine, 4-piperazine-3-pyridine, 3-tert-butyl-phenyl, 3-morpholine-phenyl, 4N-boc-piperidine-3-phenyl, and 3-isopropyl-phenyl, or a pharmaceutically acceptable salt thereof, or diastereomers thereof; and
a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1, 2, 3, 4)

The pharmaceutical formulation of any one of claims 1-4, wherein the pharmaceutical acceptable carrier is a polymer.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The pharmaceutical formulation of any one of claims 1-5, wherein the pharmaceutical acceptable carrier is a polymer selected from the group consisting of vinylpyrollidone-vinyl acetate copolymers (Kollidon VA64), amino methacrylate copolymer (Eudragit EPO), Hydroxypropylmethylcellulose E3 (HPMC E3), or a combination thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The pharmaceutical formulation of any one of claims 1-6, wherein the pharmaceutical acceptable carrier is a polymer in an amount of between about 40% and 80% of the total solids content.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The pharmaceutical formulation of any one of claims 1-7, wherein the pharmaceutical acceptable carrier is a polymer in an amount of between about 40% and 60%, 50% and 80%, 40% and 50%, or 60% and 70% of the total solids content.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The pharmaceutical formulation of any one of claims 1-8, wherein the pharmaceutical acceptable carrier is a polymer in an amount of about 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80% of the total solids content.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The pharmaceutical formulation of any one of claims 1-9, wherein the polymer is vinylpyrollidone-vinyl acetate copolymers (Kollidon VA64) in an amount of about 40 to 80% of the total solids content.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The pharmaceutical formulation of any one of claims 1-10, wherein the compound of Formula (I) is in an amount between about 1 mg to about 1,000 mg.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The pharmaceutical formulation of any one of claims 1-11, wherein the compound of Formula (I) is in an amount between about 1 mg to 100 mg; 250 mg to 500 mg, or 250 mg to 750 mg.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The pharmaceutical formulation of any one of claims 1-12, wherein the compound of Formula (I) is in an amount of about 5 mg, 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 205 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585 mg, 590 mg, 595 mg, 600 mg, 605 mg, 625 mg, 655 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, or 1,000 mg.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The pharmaceutical formulation of any one of claims 1-13, wherein Compound 1, Compound 2, Compound 3, or a combination thereof is in an amount between about 1 mg to about 1,000 mg.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The pharmaceutical formulation of any one of claims 1-14, wherein Compound 1, Compound 2, Compound 3, or a combination thereof is in an amount between about 1 mg to 100 mg; 250 mg to 500 mg, or 250 mg to 750 mg.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The pharmaceutical formulation of any one of claims 1-15, wherein Compound 1, Compound 2, Compound 3, or a combination thereof is in an amount of about 5 mg, 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 205 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585 mg, 590 mg, 595 mg, 600 mg, 605 mg, 625 mg, 655 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, or 1,000 mg.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The pharmaceutical formulation of any one of claims 1-16, wherein the formulation further comprises a pharmaceutically acceptable carrier, additive, excipient, preservative, solvent, buffer, or a mixture thereof.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The pharmaceutical formulation of any one of claims 1-17, wherein the formulation is suitable for oral administration.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The pharmaceutical formulation of any one of claims 1-18 formulated for use as a therapeutic agent in the treatment or prevention of 12-LOX mediated diseases and disorders.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A pharmaceutical composition for treating or preventing a 12-LOX mediated disease and/or disorder comprising the pharmaceutical formulation of any one of claims 1-19.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A pharmaceutical composition for reducing PAR1-AP or PAR4-AP induced platelet aggregation comprising the pharmaceutical formulation of any one of claims 1-19.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A pharmaceutical composition for reducing PAR4-AP induced calcium mobilization comprising the pharmaceutical formulation of any one of claims 1-19.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A pharmaceutical composition for reducing PAR4-AP induced calcium mobilization comprising the pharmaceutical formulation of any one of claims 1-19.

### Claim 24 (depends on 20, 21, 22, 23)

The pharmaceutical compositions of any one of claims 20-23, wherein the pharmaceutical formulation is formulated for oral administration.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method for treating or preventing a 12-LOX mediated disease and/or disorder comprising administering the pharmaceutical formulation of any one of claims 1-19 to a mammal in need thereof.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method for reducing PAR1-AP or PAR4-AP induced platelet aggregation comprising orally administering to a mammal thereof the pharmaceutical formulation of any one of claims 1-19.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method for reducing PAR4-AP induced calcium mobilization comprising orally administering to a mammal thereof the pharmaceutical formulation of any one of claims 1-19.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for treating U46619-induced and FcγRIIa-mediated platelet aggregation comprising orally administering to a mammal thereof the pharmaceutical formulation of any one of claims 1-18.

### Claim 29 (depends on 25, 26, 27, 28)

The method of any one of claims 25-28, wherein the mammal is a human.

### Claim 30 (depends on 25, 26, 27, 28, 29)

The method of any one of claims 25-29, wherein the subject in need thereof has a 12-LOX mediated disease and/or disorder.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

The method of any one of claims 25-30, wherein the 12-LOX mediated disease and/or disorder is selected from the group consisting of: as skin diseases and platelet hemostasis, transplantation/xenotransplantation, cancer, optionally prostate cancer, colorectal cancer, breast cancer and lung cancer, type 1 and type 2 diabetes, diabetic nephropathy, optionally diabetic nephropathy, diabetic retinopathy, lupus, cardiovascular disease, optionally myocardial infarction, congestive heart failure, heart failure, and stroke, thrombosis, heparin-induced thrombocytopenia (HIT), Alzheimer's disease, non-alcoholic steatohepatitis, insulin resistance, and inflammation.
